Voice evaluation in asthma patients using inhaled corticosteroids

Yıl 2016, Cilt: 26 Sayı: 2, 101 - 108, 10.05.2016

Hatem Ezzeldin Hassen Ahmed Mohamed Abo Hasseba

Öz

Objectives: This study aims to assess voice changes and laryngeal abnormalities in asthmatic patients using inhaled corticosteroids ICSs . Patients and Methods: This study included 30 patients 15 females; mean age 21.3±2.6 years; range, 17 to 26 years and 15 males; mean age 20.7±2.3 years; range, 16 to 27 years with bronchial asthma treated with ICSs between May 2013 and December 2013. A speech sample from each patient was evaluated by two phoniatricians and the degrees of dysphonia were scored. Each patient’s voice was acoustically analyzed using the multidimensional voice program software. Videolaryngoscopy was used to detect laryngeal abnormalities including the vocal folds. Results: A total of 53.3% of ICSs users had dysphonia; most of them had a mild degree dysphonia. Of patients, vocal folds erythema was present in 56.7%, interarytenoid thickening in 56.7%, vocal folds bowing in 5.3% and vocal fold atrophy in 5.5%. A total of 36.7% patients had manifestations of laryngopharyngeal reflux. The presence of vocal fold bowing and atrophy was significantly related to the duration of ICS use p=0.048 . Soft phonation index values were positively associated with the duration of the ICS use p=0.013 . Conclusion: Inhaled corticosteroids have abnormally adverse effects both on the function and the structure of the vocal folds.

Anahtar Kelimeler

Asthma, inhaled steroid, voice disorder

İnhaler kortikosteroid kullanan astım hastalarında ses değerlendirmesi

Öz

Amaç: Bu çalışmada inhaler kortikosteroid kullanan astım hastalarında ses değişiklikleri ve larenks anormallikleri değerlendirildi.Hastalar ve Yöntemler: Bu çalışmaya Mayıs 2013 - Aralık 2013 tarihleri arasında İKS ile tedavi edilen bronşiyal astımlı 30 hasta 15 kadın; ort. yaş 21.3±2.6 yıl; dağılım, 17-26 yıl ve 15 erkek; ort. yaş 20.7±2.3 yıl; dağılım 16-27 yıl alındı. Her hastanın konuşma örneği iki foniatrist tarafından değerlendirildi ve disfoni dereceleri skorlandı. Her hastanın sesi çok boyutlu ses programı yazılımı ile akustik olarak analiz edildi. Ses telleri dahil larenks anormalliklerini tespit etmek amacıyla videolarengoskopi kullanıldı. Bulgular: İnhaler kortikosteroid İKS kullananların toplam %53.3’ünde disfoni vardı, bunların çoğunda disfoni derecesi hafifti. Hastaların %56.7’sinde ses tellerinde eritem, %56.7’sinde interaritenoid kalınlaşma, %5.3’ünde ses tellerinde sarkma ve %5.5’inde ses tellerinde atrofi vardı. Hastaların toplam 36.7’sinde larengofarengeal reflü bulgusu vardı. Ses tellerinde sarkma ve atrofi, anlamlı olarak İKS kullanım süresi ile ilişkilendirildi p=0.048 . Yumuşak fonasyon indeks değerleri, İKS kullanım süresi ile pozitif olarak ilişkiliydi p=0.013 .Sonuç: İnhaler kortikosteroidler ses tellerinin hem fonksiyonu hem de yapısı üzerinde anormal advers etkiye sahiptir

Anahtar Kelimeler

Astım, inhaler steroid, ses patolojisi

Kaynakça

• Eva I, Olle Z, Elisabeth I, Britta H. voice problems as side effects of inhaled corticosteroids in asthma patients-A prevalence study. Journal of Voice 2004;18:403-11.
• Holgate ST. Pathogenesis of asthma. In: Kay AB, Kaplan AB, Bousquet J, Holt PG, editors. Allergy and Allergic Diseases. 2nd ed. Oxford: Blackwell Publishing Ltd; 2008. p. 1608-31.
• Boner AL, Piacentini GL. Inhaled corticosteroids in children. Is there a 'safe' dosage? Drug Saf 1993;9:9-20.
• Nerbrink O, Dahlbäck M. Basic nebulizer function. J Aerosol Med 1994;7:7-11.
• Kotby MN. The accent method of voice therapy. San Diego: Singular Publishing Group; 1995. p. 3-21.
• Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 1995;8:590-2.
• Toogood JH, Jennings B, Greenway RW, Chuang L. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 1980;65:145-53.
• Tarlo SM, Broder I, Davies GM, Leznoff A, Mintz S, Corey PN. Six-month double-blind, controlled trial of high dose, concentrated beclomethasone dipropionate in the treatment of severe chronic asthma. Chest 1988;93:998-1002.
• Goldberg J, Kovarsky J. Beclomethasone dipropionate inhalation treatment for chronic hoarseness in rheumatic disease. Arthritis Rheum 1983;26:1412.
• Clark PM, Durham SR, Perry A, Mackay IS. Objective measurements of voice changes caused by inhaled steroids. Voice 1992;1:63-6.
• Dong JC, Shen ZY, Wang WJ. The investigation on 100 bronchial asthma and asthmatic bronchitis cases treated with high dose beclomethasone dipropionate aerosol. Zhonghua Jie He He Hu Xi Za Zhi 1993;16:33-5.
• Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-208.
• Lavy JA, Wood G, Rubin JS, Harries M. Dysphonia associated with inhaled steroids. J Voice 2000;14:581-8.
• Saini B, LeMay K, Emmerton L, Krass I, Smith L, Bosnic- Anticevich S, et al. Asthma disease management- Australian pharmacists' interventions improve patients' asthma knowledge and this is sustained. Patient Educ Couns 2011;83:295-302.
• Bhalla RK, Watson G, Taylor W, Jones AS, Roland NJ. Acoustic analysis in asthmatics and the influence of inhaled corticosteroid therapy. J Voice 2009;23:505-11.
• Gallivan GJ, Gallivan KH, Gallivan HK. Inhaled corticosteroids: hazardous effects on voice-an update. J Voice 2007;21:101-11.
• Torre P, Barlow JA. Age-related changes in acoustic characteristics of adult speech. J Commun Disord 2009;42:324-33.
• Williams AJ, Baghat MS, Stableforth DE, Cayton RM, Shenoi PM, Skinner C. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax 1983;38:813-21.
• DelGaudio JM. Steroid inhaler laryngitis: dysphonia caused by inhaled fluticasone therapy. Arch Otolaryngol Head Neck Surg 2002;128:677-81.
• Shaw NJ, Edmunds AT. Inhaled beclomethasone and oral candidiasis. Arch Dis Child 1986;61:788-90.
• Balter MS, Adams SG, Chapman KR. Inhaled beclomethasone dipropionate improves acoustic measures of voice in patients with asthma. Chest 2001;120:1829-34.
• Barnes PJ. Corticosteroids, IgE, and atopy. J Clin Invest 2001;107:265-6.
• Ozbilen Acar G, Uzun Adatepe N, Kaytaz A, Edizer DT, Gemicioglu B, Yagiz C, et al. Evaluation of laryngeal findings in users of inhaled steroids. Eur Arch Otorhinolaryngol 2010;267:917-23.
• Humbert M, Andersson TL, Buhl R. Budesonide/ formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy 2008;63:1567-80.
• Mirza N, Kasper Schwartz S, Antin-Ozerkis D. Laryngeal findings in users of combination corticosteroid and bronchodilator therapy. Laryngoscope 2004;114:1566-9.
• Ishizuka T, Hisada T, Aoki H, Yanagitani N, Kaira K, Utsugi M, et al. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma. Allergy Asthma Proc 2007;28:550-6.
• Kosztyła-Hojna B, Rogowski M, Rutkowski R, Pepiński W, Ryćko P. Influence of treatment of inhaled corticosteroids on the function of the larynx in asthmatic patients. Pol Merkur Lekarski 2006;20:145- 50. [Abstract]
• Krecicki T, Liebhart J, Morawska-Kochman M, Liebhart E, Zatoński M, Zalesska-Krecicka M. Corticosteroid- induced laryngeal disorders in asthma. Med Sci Monit 2006;12:351-4.
• Babu S, Samuel P. The effect of inhaled steroids on the upper respiratory tract. J Laryngol Otol 1988;102:592-4.
• Dogan M, Eryuksel E, Kocak I, Celikel T, Sehitoglu MA. Subjective and objective evaluation of voice quality in patients with asthma. J Voice 2007;21:224-30.
• Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006;100:1307-17.
• Watts CR, Clark R, Early S. Acoustic measures of phonatory improvement secondary to treatment by oral corticosteroids in a professional singer: a case report. J Voice 2001;15:115-21.
• Watkin KL, Ewanowski SJ. The effects of triamcinolone acetonide on the voice. J Speech Hear Res 1979;22:446-55.